The evolution in the prioritization for liver transplantation

Annals of Gastroenterology

Volumn 25, Issue 1, 2012, Pages 6-13

  Cholongitas, Evangelos ^a,b   Burroughs, Andrew K ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Allocation; Liver transplantation; MELD score; Survival benefit; UKELD score

Indexed keywords

SODIUM;

CHILD TURCOTTE PUGH SCORE; DIAGNOSTIC ACCURACY; GRAFT RECIPIENT; HEALTH CARE POLICY; HUMAN; LABORATORY TEST; LIVER TRANSPLANTATION; MODEL FOR END STAGE LIVER DISEASE SCORE; ORGAN DONOR; PREDICTIVE VALUE; PROGNOSIS; REVIEW; SCORING SYSTEM; SODIUM BLOOD LEVEL; SURVIVAL; UNITED KINGDOM MODEL FOR END STAGE LIVER DISEASE SCORE; VALIDATION STUDY;

EID: 84856839899     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Adam R, Hoti E. Liver transplantation: the current situation. Semin Liver Dis 2009;29:3-18.
2. Cholongitas E, Papatheodoridis G V, Vangeli M, et al. Systematic review: the model for end-stage liver disease - should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther 2005;22:1079-1089.
3. Freeman RB, Jamieson N, Schaubel DE, et al. Who should get a liver graft? J Hepatol 2009;50:664-673.
4. Durand F, Valla D. Assessment of prognosis of cirrhosis. Semin Liver Dis 2008;28:110-122.
5. Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 2008;57:252-257.
6. Asrani S, Kim WR. Organ allocation for chronic liver disease: model for end-stage liver disease and beyond. Curr Opin Gastroenterol 2010;26:209-213.
7. Feng S, Goodrich N P, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006;6:783-790.
8. Pugh R, Murray-lyon I, Dawson J. Transcection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
9. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores--where are we and where should we go? J Hepatol 2004;41:344-350.
10. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 2005;42 Suppl(1):S100-S107.
11. Cholongitas E, Shusang V, Marelli L, et al. Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther 2007;26:969-978.
12. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-871.
13. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-470.
14. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
15. Cholongitas E, Marelli L, Shusang V, et al. A systematic review of the performance of the model for end-stage liver disease (MELD) in the setting of liver transplantation. Liver Transpl 2006;12:1049-1061.
16. Attia KA, Ckoundou-N'guessan KC, N'dri-Yoman AT, et al. Child-Pugh-Turcott versus Meld score for predicting survival in a retrospective cohort of black African cirrhotic patients. W o r l d J Gastroenterol 2008;14:286-291.
17. Boursier J, Cesbron E, Tropet AL, et al. Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6-month mortality in cirrhotic patients. J Clin Gastroenterol 2009;43:580-585.
18. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-313.
19. Wiesner RH. Patient selection in an era of donor liver shortage: current US policy. Nat Clin Pract Gastroenterol Hepatol 2005;2:24-30.
20. Freeman R, Wiesner R, Edwards E. Results of the first year of the new liver allocation plan. Liver Transpl 2004;10:7-15.
21. Trotter JF, Brimhall B, Arjal R, et al. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Tr a n s p l 2004;10:995-1000.
22. Porte RJ, Lisman T, Tripodi A, et al. The International Normalized Ratio (INR) in the MELD score: problems and solutions. Am J Transplant 2010;10:1349-1353.
23. Goulding C, Cholongitas E, Nair D, et al. Assessment of reproducibility of creatinine measurement and MELD scoring in four liver transplant units in the UK. Nephrol Dial Transplant 2010;25:960-966.
24. Cholongitas E, Marelli L, Kerry A, et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Tr a n s p l 2007;13:523-529.
25. Sharma P, Schaubel DE, Sima CS, et al. Re-weighting the model for end-stage liver disease score components. Gastroenterology 2008;135:1575-1581.
26. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933-1953.
27. Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med 1988;39:465-490.
28. Cholongitas E, Marelli L, Kerry A, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores--a systematic bias. Am J Transplant 2007;7:685-692.
29. Moylan CA, Brady C W, Johnson JL, et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008;300:2371-2378.
30. Cholongitas E, Germani G, Tsochatzis E, et al. Towards a better liver allocation system. J Hepatol 2009;51:827-828.
31. Huo S, Huo T, Lin H, et al. Is the corrected-creatinine model for end-stage liver disease a feasible strategy to adjust gender difference in organ allocation for liver transplantation? Transplantation 2007;84:1406-1412.
32. 51Cr-EDTA clearance in patients with cirrhosis. Clin J Am Soc Nephrol 2010;6:84-92.
33. Somsouk M, Guy J, Biggins S W, et al. Ascites improves upon [corrected] serum sodium plus [corrected] model for end-stage liver disease (MELD) for predicting mortality in patients with advanced liver disease. Aliment Pharmacol Ther 2009;30:741-748.
34. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality 4-fold and should be used in determining prognosis. Gastroenterology 2010;139:1246-1256.
35. Atkinson M, Paton A, Sherlock S. Control of ascites in hepatic cirrhosis. Lancet 1954;266:128-129.
36. Sherlock S, Summerkill WH, White L P, et al. Portal-systemic encephalopathy; neurological complications of liver disease. Lancet 1954;267:454-457.
37. Londono MC, Cardenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007;56:1283-1290.
38. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-1026.
39. Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007;13:1174-1180.
40. Barber K, Pioli S, Blackwell J. Development of a UK score for patients with end-stage liver disease. Hepatology 2007;46:510A.
41. Barber K, Madden S, Allen J, et al. Elective liver transplant list mortality: development of a United Kingdom end-stage liver disease score. Transplantation 2011;92:469-476.
42. Xiol X, Gines P, Castells L, et al. Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease-sodium scores determined at three university-based laboratories of the same area. Liver Transpl 2009;15:300-305.
43. Heuman DM, Mihas AA, Habib A, et al. MELD-XI: a rational approach to"sickest first" liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl 2007;13:30-37.
44. Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007;46:520-527.
45. Thuluvath PJ, Guidinger MK, Fung JJ, et al. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010;10(4 Pt 2):1003-1019.
46. Gonwa TA, McBride MA, Anderson K, et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006;6:2651-2659.
47. Leise MD, Kim WR, Kremers WK, et al. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011;140:1952-1960.
48. Huo TI, Wu JC, Lin HC, et al. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. J Hepatol 2005;42:826-832.
49. Merion RM, Wolfe RA, Dykstra DM, et al. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Tr a n s p l 2003;9:12-18.
50. Bambha K, Kim WR, Kremers WK, et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant 2004;4:1798-1804.
51. Choi PC, Kim HJ, Choi WH, et al. Model for end-stage liver disease, model for end-stage liver disease-sodium and Child-Turcotte-Pugh scores over time for the prediction of complications of liver cirrhosis. Liver Int 2009;29:221-226.
52. Bae WK, Lee JS, Kim NH, et al. [Usefulness of DeltaMELD/ month for prediction of the mortality in the first episode of variceal bleeding patients with liver cirrhosis: comparison with CTP, MELD score and DeltaCTP/month]. Korean J Hepatol 2007;13:51-60.
53. Jacob M, Copley L P, Lewsey JD, et al. Pretransplant MELD score and post liver transplantation survival in the UK and Ireland. Liver Transpl 2004;10:903-907.
54. Desai NM, Mange KC, Crawford MD, et al. Predicting outcome after liver transplantation: utility of the model for end-stage liver disease and a newly derived discrimination function. Transplantation 2004;77:99-106.
55. Nagler E, Van Vlierberghe H, Colle I, et al. Impact of MELD on short-term and long-term outcome following liver transplantation: a European perspective. Eur J Gastroenterol Hepatol 2005;17:849-856.
56. Burroughs AK, Marelli L, Cholongitas E, et al. Towards a better liver transplant allocation system. Liver Transpl 2007;13:935-936.
57. Halldorson JB, Bakthavatsalam R, Fix O, et al. D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. Am J Transplant 2009;9:318-326.
58. Burroughs AK, Sabin CA, Rolles K, et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet 2006;367:225-232.
59. Ioannou GN. Development and validation of a model predicting graft survival after liver transplantation. Liver Transpl 2006;12:1594-1606.
60. Schaubel DE, Sima CS, Goodrich N P, et al. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008;8:419-425.
61. Schaubel DE, Guidinger MK, Biggins SW et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009;9(4 Pt 2):970-981.
62. Ravaioli M, Grazi GL, Dazzi A, et al. Survival benefit after liver transplantation: a single European center experience. Transplantation 2009;88:826-834.
63. Egan TM, Murray S, Bustami RT, et al. Development of the new lung allocation system in the United States. Am J Transplant 2006;6(5 Pt 2):1212-1227.
64. Huo TI, Lin HC, Huo SC, et al. Comparison of four model for end-stage liver disease-based prognostic systems for cirrhosis. Liver Transpl 2008;14:837-844.
65. Biselli M, Gitto S, Gramenzi A, et al. Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? Liver Transpl 2010;16:964-973.
66. Cucchetti A, Vivarelli M, Heaton ND, et al. Artificial neural network is superior to MELD in predicting mortality of patients with end-stage liver disease. Gut 2007;56:253-258.
67. Lucey MR. How will patients be selected for transplantation in the future? Liver Transpl 2004;10(10 Suppl 2):S90-S92.
68. Martin A P, Bartels M, Hauss J, et al. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc 2007;39:3169-3174.
69. Byrne T, Douglas D, Lopez J, et al. Does MELD score influence post-transplant quality of life? Hepatology 2004;40:765A.
70. Kamath PS, Kim WR. Is the change in MELD score a better indicator of mortality than baseline MELD score? Liver Transpl 2003;9:19-21.
71. Neuberger J. Allocation of donor livers--is MELD enough? Liver Tr a n s p l 2004;10:908-910.
72. Freeman RB. Mathematical models and behavior: assessing delta MELD for liver allocation. Am J Transplant 2004;4:1735-1736.
73. Weismuller TJ, Negm A, Becker T, et al. The introduction of MELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics. Transpl Int 2009;22:970-978.
74. Foxton MR, Al-Freah MA, Portal AJ, et al. Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs. Liver Transpl 2010;16:668-677.
75. Cholongitas E, Germani G, Burroughs AK. Prioritization for liver transplantation. Nat Rev Gastroenterol Hepatol 2010;7:659-668.